Cooley advised Isis Pharmaceuticals, Inc. on its Rule 144A offering of $500 million aggregate principal amount of convertible senior notes due 2021. The initial purchasers have purchased $15 million aggregate principal amount of convertible notes.
Isis is the leading company in antisense drug discovery and development; exploiting a proven, novel drug discovery platform designed to generate a pipeline of first-in-class drugs.
The Cooley team advising Isis Pharmaceuticals was led by partners Charlie Kim, Gian-Michele a Marca and Sean Clayton, and included associates Jon Russo, Jason Savich, Phillip McGill and Adrienne Directo. Critical support was also provided by partner Natasha Leskovsek (health care and life sciences regulatory); and partners Susan Cooper Philpot and Mark Windfeld-Hansen (tax).
Related Posts:
- Davis Polk – Isis Pharmaceuticals, Inc. $201.25 Million Convertible Senior Notes Offering
- FireEye Completes 144A Private Placement of $920 Million Convertible Senior Notes
- Cooley Advises Jazz Pharmaceuticals plc on Rule 144A Offering of $575 Million of Exchangeable Senior Notes
- Cooley Represents Brocade in $300 Million 4.625 % Senior Notes Offering
- Davis Polk – Isis Pharmaceuticals, Inc. Common Stock Offering
